A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

NCT00336310 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Repaglinide

Sponsor

National Cheng-Kung University Hospital